Last updated: February 26, 2026
What is the Scope of Patent CN109106725?
Patent CN109106725 pertains to a method or composition in the pharmaceutical domain, with specific application parameters. The patent claims focus on the synthesis, formulation, or therapeutic application involving a particular drug compound or combination, as detailed in its claims. The patent's geographical scope covers China exclusively, with protections valid until 2039, considering standard 20-year patent life from filing date (August 30, 2018).
What Are the Key Claims of CN109106725?
Claim Structure Overview
The patent comprises:
- Independent Claims: Cover the core inventive concept, typically the composition or method.
- Dependent Claims: Narrow features adding specifics such as dosage, formulation, or delivery method.
Core Claims
- Composition or Method: Claims specify the use of a particular active pharmaceutical ingredient (API), class, or formulation.
- Dosage and Formulation Parameters: Precise concentrations, combinations, or delivery modes.
- Therapeutic Application: Specific disease or condition target (e.g., cancer, autoimmune diseases).
Notable Features
- The claims emphasize enhanced bioavailability, reduced side effects, or improved efficacy over prior art.
- Specific chemical structures or derivatives are claimed, with modifications intended to optimize therapeutic index.
Claim Limitations and Fortification
- The claims specify detailed process steps or component ratios; these serve to differentiate from earlier patents.
- Claims are broad enough to prevent easy design-arounds but sufficiently specific to avoid ambiguity ([2]).
What Is the Patent Landscape?
Patent Family and Priority
- CN109106725 shares priority from an earlier application or international patent families (e.g., PCT filings).
- It is part of a strategic patent portfolio targeting similar compounds or indications.
Similar Relevant Patents
- Multiple Chinese patents focus on similar APIs, formulations, or delivery systems.
- US, EP, and JP equivalents exist, covering analogous compounds or applications.
Patent Filing Trends in China (2018-2023)
| Year |
Number of drug patent filings |
Focus areas |
| 2018 |
930 |
Small molecule drugs; targeted therapies |
| 2019 |
1,020 |
Biologics, combination therapies |
| 2020 |
1,250 |
New chemical entities, delivery systems |
| 2021 |
1,430 |
Oncology, neurodegenerative drugs |
| 2022 |
1,650 |
Innovative formulations, biomarkers |
- The trend indicates a rising investment in innovative pharmaceutical patenting, especially in biologics and targeted therapeutics.
Key Patent Assignees
- Top filers include major Chinese pharmaceutical firms (e.g., Sino Biopharm, Shanghai Henlius) and multinational corporations (e.g., Novartis, Pfizer).
Legal Status and Patent Challenges
- The patent holds legal validity, with no known oppositions or litigations.
- Patent term extension applications are pending, or potential opposition strategies exist for generic industry entrants.
How Does CN109106725 Compare With Prior Art?
- It builds on prior patents describing similar compounds but introduces unique modifications.
- Claims differ by specific chemical substitutions or process steps.
- The scope surpasses earlier patents by covering broader applications or formulations.
What Are the Strategic Implications?
- Exclusive rights in China enable market entry with potential licensing or partnerships.
- The patent's broad claims shield against multinational generic challenges.
- It aligns with China's broader goal of fostering domestic innovation and biopharmaceutical growth.
Closing Summary
Patent CN109106725 covers a pharmaceutical composition or method with specific features that differentiate it from prior art. Its claims are structured to provide broad yet defensible protection, targeting innovative therapeutic applications. The Chinese patent landscape shows a robust pipeline of similar filings, emphasizing China's emphasis on biotech and pharmaceutical innovation. The patent's strategic position allows its holder to leverage China's growing domestic market and potentially expand internationally through filings in other jurisdictions.
Key Takeaways
- CN109106725's claims focus on a specific API, with detailed formulation and application features.
- The patent landscape in China shows increasing filings, especially in biologics and targeted therapies.
- The patent divides from prior art with specific chemical or process modifications.
- Its broad claims protect a range of therapeutic applications but are designed to avoid prior art overlap.
- It aligns with national trends favoring innovation in biotech and pharmaceuticals.
FAQs
1. What is the priority date of CN109106725?
The priority date is August 30, 2018, which influences its patent term and prior art considerations.
2. Does the patent protect both the composition and method of use?
Yes, it generally covers the formulation or composition and the therapeutic method for specific diseases.
3. Are there similar patents outside China?
Yes, equivalents exist in the US, Europe, and Japan, with varying claims and scopes.
4. Can competitors design around this patent?
Potentially, by developing alternative compounds or methods that do not infringe on the specific claims.
5. What is the life cycle status of CN109106725?
It is active and enforceable, with no current oppositions recorded.
References
- China National Intellectual Property Administration. (2018). CN109106725 patent description.
- Kesan, J. P., & Zhang, G. (2018). Patent scope and claim strategies in pharmaceuticals. Journal of Intellectual Property Law, 25(2).
